# Phase 1 glioblastoma trials recruiting: 73 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 73 trials in phase 1 for glioblastoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 glioblastoma trials: 73 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/glioblastoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 73
- Recruiting or not yet: 73
- Read on: November 19, 2026

## Trials

The 25 newest of 73, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07930338 | First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma | YGION Biomedical GmbH | Phase 1 | Not yet recruiting | Glioblastoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930338) |
| November 10, 2026 | NCT07929909 | A Phase I Clinical Study of YN003 in the Treatment of Glioma | Beijing Inno Medicine Co., Ltd. | Phase 1 | Recruiting | Glioma, Glioblastoma, Brain Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929909) |
| October 7, 2026 | NCT07862647 | TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma | Alpheus Medical, Inc. | Phase 1 | Recruiting | Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862647) |
| August 27, 2026 | NCT07791264 | FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma | City of Hope Medical Center | Phase 1 | Not yet recruiting | Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791264) |
| July 31, 2026 | NCT07739017 | OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma | Olivia Newton-John Cancer Research Institute | Phase 1 | Not yet recruiting | Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739017) |
| July 29, 2026 | NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma... | Radiomedix, Inc. | Phase 1 | Recruiting | Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733674) |
| June 12, 2026 | NCT07643870 | Human ADME Study of \[14C\]-AZD1390 | AstraZeneca | Phase 1 | Not yet recruiting | Advanced Solid Malignancies | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643870) |
| May 12, 2026 | NCT07579208 | A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor... | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579208) |
| May 1, 2026 | NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | Masonic Cancer Center, University of Minnesota | Phase 1 | Recruiting | Astrocytoma, Glioblastoma, Progressive Disease | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560865) |
| April 24, 2026 | NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | Beijing Biotech | Phase 1 | Recruiting | Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas, Recurrent Glioblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551336) |
| April 22, 2026 | NCT07544992 | Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive... | City of Hope Medical Center | Phase 1 | Recruiting | Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544992) |
| April 21, 2026 | NCT07541781 | Sitagliptin in Recurrent/Progressive Grade 4 Glioma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541781) |
| April 13, 2026 | NCT07524140 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors | Eilean Therapeutics | Phase 1 | Recruiting | Advanced Solid Tumor Cancer, Metastatic Solid Tumor | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524140) |
| March 18, 2026 | NCT07480941 | Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma | Beijing Biotech | Phase 1 | Recruiting | Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent High-grade Glioma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480941) |
| March 11, 2026 | NCT07464925 | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | Tetragon Biosciences Ltd | Phase 1 | Recruiting | Glioblastoma Multiforme of Brain, Glioma, Glioblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464925) |
| March 6, 2026 | NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455045) |
| February 20, 2026 | NCT07422896 | A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Glioblastoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07422896) |
| February 20, 2026 | NCT07422363 | Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent... | National Cancer Institute (NCI) | Phase 1 | Not yet recruiting | Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07422363) |
| February 4, 2026 | NCT07385846 | Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Glioblastoma, Mismatch Repair Deficiency | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07385846) |
| January 15, 2026 | NCT07343986 | Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma | University of Virginia | Phase 1 | Recruiting | Glioblastoma (GBM) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343986) |
| November 24, 2025 | NCT07244835 | A Study of DEG6498 in Participants With Solid Tumors | Degron Therapeutics Co. | Phase 1 | Recruiting | Malignant Neoplasms | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244835) |
| October 31, 2025 | NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223034) |
| October 20, 2025 | NCT07218367 | Phase I Trial of pH Resections of GBM at VA | VA Office of Research and Development | Phase 1 | Not yet recruiting | Glioblastoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218367) |
| September 26, 2025 | NCT07193628 | B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1 | Recruiting | Refractory Glioblastoma, Recurrent Glioblastoma | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193628) |
| September 17, 2025 | NCT07179328 | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | Sunnybrook Health Sciences Centre | Phase 1 | Recruiting | GBM, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme of Brain, Glioblastoma Multiforme Glioma, HGG, Glioma... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179328) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| City of Hope Medical Center | 4 |
| M.D. Anderson Cancer Center | 3 |
| National Cancer Institute (NCI) | 3 |
| Mayo Clinic | 2 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| University of Florida | 2 |
| Degron Therapeutics Co. | 1 |
| Shenzhen Geno-Immune Medical Institute | 1 |
| RasCal Therapeutics, Inc. | 1 |
| Olivia Newton-John Cancer Research Institute | 1 |
| Case Comprehensive Cancer Center | 1 |
| Alpheus Medical, Inc. | 1 |
| BeyondBio Inc. | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Radiomedix, Inc. | 1 |
| Joint Stock Company European Medical Centre | 1 |
| Northwestern University | 1 |
| Crimson Biopharm Inc. | 1 |
| Beijing Tricision Biotherapeutics Inc | 1 |
| Baylor College of Medicine | 1 |
| Hospital San Carlos, Madrid | 1 |
| University of California, Los Angeles | 1 |
| Henry Ford Health System | 1 |
| YGION Biomedical GmbH | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 49 |
| China | 10 |
| Australia | 3 |
| United Kingdom | 3 |
| South Korea | 2 |
| Switzerland | 2 |
| Russia | 1 |
| Spain | 1 |
| Austria | 1 |
| Canada | 1 |
| Netherlands | 1 |
| Belgium | 1 |
| France | 1 |
| Japan | 1 |
| Uzbekistan | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bearing suppliers in the United States](https://specstream.ai/data/businesses/bearing-suppliers/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Pediatric orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-orthopedic-surgery-practices/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
